Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,356 total articles
Adobe remains one of the highest-quality software franchises in the market. With a resilient Creative Cloud ecosystem, recurring revenue, and expanding margin optionality, a pullback creates an asymmetric opportunity. This trade idea outlines a mid-term buy with clear entry, stop, and target levels and practical reasons to own the stock into cataly…
Global Ship Lease (GSL) offers a compelling mix of current income and upside. The company sits on $2.24 billion of contracted revenue (3.6 years including options), pays a $0.625 quarterly dividend (annualized $2.50) and yields roughly 6% at current levels. With a relatively modest market cap of $1.37 billion, a fleet of 71 containerships under lon…
<p>Duolingo has reset priorities from near-term monetization back to user growth. That shift dented guidance and the stock in early 2026, but it also buys time to improve engagement and product-led conversion. At current multiples and a market cap under $5 billion, the risk/reward looks asymmetric for investors willing to hold into 2027 if manageme…
Cartesian Therapeutics is an under-the-radar clinical-stage immuno-oncology name running a Phase 3 program that, if positive, could validate mRNA-delivered CAR-T as a scalable alternative to autologous cell therapy. This trade idea lays out a directional long trade sized for high-risk biotech exposure, a clear entry at $6.50, a primary target at $1…
KKR is a capital-allocation machine whose fee-bearing business and recent realizations create a path for earnings compounding. The stock has reset from last year's highs and now trades at $105.93 with a market cap near $95B. We initiate a tactical long with a $105.93 entry, $95 stop and $130 target over a 180-trading-day horizon, citing deal flow, …
Sun Life (SLF) is trading near its 52-week high on headline strength: $70.49, PE ~16, PB ~2.4 and a 3.7% yield. Fundamentals and cash returns support owning the name, but momentum is extended (RSI ~76). We outline a mid-term actionable long with a clear entry, stop and target and a balanced risk framework.
Northrop Grumman (NOC) reported solid Q1 results, is expanding B-21 capacity, and sits squarely in the path of a materially higher U.S. defense budget. The stock is deeply oversold after a sharp pullback; fundamentals and cash flow support a tactical long with defined risk controls.
Getty Realty remains a reliable net-lease REIT with a 5.6% yield, a 1,174-property portfolio, and a recent equity raise to fund acquisitions and debt reduction. The balance of steady cash income and modest cap appreciation makes GTY a tactical long for a 180-trading-day position, provided investors respect a defined stop-loss.
Intuitive Surgical (ISRG) reported a strong Q1 with revenue and EPS beats, raised procedure growth and margin guides, and sits on a powerful recurring-revenue flywheel. Yes, headline P/E looks rich today (~59x), but the company converts market leadership and high gross margins into steady free cash flow growth. This trade idea buys that secular sto…
Pan American Silver (PAAS) has momentum behind it as silver trades near $80/oz. Fundamentals and exploration upside support more upside from current levels, but valuation and operational risks require a disciplined entry and stop. This trade idea lays out a mid-term (45 trading days) plan to capture upside to $70 while limiting downside to $50.
Manhattan Associates (MANH) combines a sticky, mission-critical product suite for supply chain and omnichannel logistics with strong cash generation and no debt. Recent pullback to $143 presents an attractive entry for investors willing to give cloud subscription momentum and margin normalization time to play out.
Travel + Leisure (TNL) plunged intraday on 4/22/2026 on headlines and a spike in short activity. Fundamentals - $523M of free cash flow, an attractive dividend yield near 3%, and an EV/FCF that is not stretched - argue the move is overdone. This trade targets a recovery to prior support near $76 with a tight stop under $61 for a mid-term swing (45 …
TUI (TUIFF) has retraced to its short-term moving averages after a geopolitical-driven selloff tied to the Iran conflict. Liquidity is thin and short interest is elevated, but momentum indicators have begun to stabilize. This trade targets a mean-reversion recovery to the 50-day moving average while keeping a tight stop to limit exposure to renewed…
Rivian looks positioned to leverage an inflection in both unit economics and addressable market with the R2 SUV. Cost reductions, improving gross margins, and meaningful liquidity commitments create a favorable risk/reward in the mid term. This trade lays out an entry, stop, and target for a 45-trading-day swing that captures early R2 demand signal…
Trulieve (TCNNF) looks like a repeatable operational story trading well below peer re-rate levels. With clear signs of bullish momentum, institutional interest and a federal rescheduling narrative heating up, this idea targets a measured long with a defined stop. The trade leans on Trulieve's margin profile, market cap, and recent volume/technical …
eBay's core marketplace is healthy - $2.97B Q4 revenue, mid-single-digit to low-double-digit GMV growth, $1.2B Depop deal to capture younger shoppers, and advertising nearing a $2B run rate. Yet the stock now trades near its 52-week high, with P/E in the mid-20s, EV/EBITDA ~19.4x and an RSI above 70. That combination pushes our stance from Buy to H…
Marvell sits at the center of AI networking and storage. A strategic tie-up or acquisition of an optics specialist like POET would plug a gap in Marvell's data-center optics stack and could justify a material multiple expansion. This trade idea lays out a long entry, stop, targets, catalysts and risks with a primary horizon of 180 trading days.
INBX exploded higher on reports that large pharmas are in early talks about a joint spin-off of INBRX-106 and another oncology asset — a combination that analysts peg at multi-billion dollar value. The move ripped the stock from the low teens to intraday highs above $155 and leaves a tradable setup for momentum traders who respect biotech risk and …
The reopening of the Strait of Hormuz removed an immediate premium, but structural shifts in global supply, U.S. export dynamics, and Diamondback's capital returns argue that oil is unlikely to return to 'cheap' levels. Diamondback Energy (FANG) offers a leveraged, cash-returning way to play sustained mid-cycle oil prices—entry $193.00, stop $175.0…
Moody's (MCO) looks buyable after a strong mix of cash flow generation, best-in-class ROE, and improving momentum. The firm's rating franchise and Moody's Analytics provide recurring, high-margin revenue that supports a premium multiple. We lay out an actionable long trade with entry, stop and target framed to capture upside while keeping risk cont…
Xenon Pharmaceuticals' positive Phase 3 X-TOLE2 results for azetukalner (53.2% median seizure reduction vs 10.4% for placebo) and robust 48-month extension data justify a tactical long position. The company is well-capitalized after a $650M offering but trades at a premium - a buy for traders willing to accept biotech binary risk into an expected Q…
Buy LSEG (London Stock Exchange Group) as a mid-term swing trade. The business benefits from recurring fee streams, growing data and analytics monetization, and a resilient market structure that generates revenue regardless of direction. Enter at $95.00, stop $84.00, target $115.00. Time the trade for a mid-term hold (45 trading days) to let cataly…
MSOS has ripped higher after federal rescheduling optimism. The ETF's liquidity, concentration in U.S. operators, and immediate technical momentum create a tradable long setup. This note lays out an entry, stop, and target with framing on catalysts, valuation, and risks.
Alphabet is entering its April 29 earnings with accelerating AI adoption across Search and Cloud, a deep balance sheet and expanding custom chip partnerships that should support continued revenue and margin expansion. This trade idea outlines a mid-term swing buy with entry, stop and target, and a risk framework that balances headline risk around t…
Kyverna Therapeutics presents a binary, high-reward trade: additional proof-of-concept (POC) data for miv-cel in myasthenia gravis could materially re-rate the stock. With limited public financial disclosure at the time of writing, this is a catalyst-driven long where position sizing should reflect binary clinical risk.
